CHEMICAL AND PHYSICAL PROPERTIES
| Color/Form | White to off-white crystalline solid |
|---|---|
| Solubility | Slightly soluble in water |
| LogP | 1.62 |
| Stability/Shelf Life | Stable if stored as directed; avoid strong oxidizing agents |
| Decomposition | Thermal decomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides. |
| Dissociation Constants | 9.3 |
COMPUTED DESCRIPTORS
| Molecular Weight | 529.5 g/mol |
|---|---|
| XLogP3 | 1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 11 |
| Exact Mass | 529.16254467 g/mol |
| Monoisotopic Mass | 529.16254467 g/mol |
| Topological Polar Surface Area | 153 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 913 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Sofosbuvir (formerly GS-7977 and PSI-7977), a potent, once-daily, orally administered nucleotide analogue prodrug inhibitor of the hepatitis C virus (HCV) NS5B polymerase is approved in the USA, EU, and other regions for the treatment of HCV infection as a component of an antiviral treatment regimen, including in combination with the NS5A inhibitor ledipasvir as HARVONI. Sofosbuvir potently inhibits genotype 1–6 HCV RNA replicons in vitro, has a high genetic barrier to resistance, and has demonstrated high sustained virologic response (SVR) rates when administered with ribavirin to subjects with chronic genotype 2 and 3 HCV infection and with pegylated interferon ＋ribavirin to subjects with chronic genotype 1, 2, 3, 4, or 6 HCV infection.